<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Babesiosis: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Babesiosis: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Babesiosis: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Krause, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edouard G Vannier, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2849126422"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Babesiosis is an infectious disease caused by protozoa of the genus <em>Babesia</em>. <em>Babesia</em> spp are transmitted primarily by tick vectors and rarely via blood transfusion, organ transplantation, or congenitally. <em>Babesia</em> protozoa invade and cause lysis of red blood cells in mammalian hosts [<a href="#rid1">1-5</a>].</p><p><em>Babesia microti</em> is the primary agent of human babesiosis in the United States, particularly in the Northeast and upper Midwest where it is endemic. Nearly all cases in Europe have been attributed to <em>Babesia divergens</em>,<em> </em>but the infection is sporadic. <em>Babesia venatorum</em> and <em>Babesia crassa</em>-like infections are endemic in northeastern China.</p><p>The treatment and prevention of babesiosis will be reviewed here. The clinical manifestations, diagnosis, microbiology, epidemiology, and pathogenesis of babesiosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5734.html" rel="external">"Babesiosis: Microbiology, epidemiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H587657468"><span class="h1">TREATMENT OF B. MICROTI INFECTION</span></p><p class="headingAnchor" id="H3106996847"><span class="h2">Immunocompetent patients</span></p><p class="headingAnchor" id="H3792848983"><span class="h3">Nonpregnant adults</span></p><p class="headingAnchor" id="H613103894"><span class="h4">Asymptomatic infection</span><span class="headingEndMark"> — </span>In general, individuals with asymptomatic infection do not warrant routine treatment [<a href="#rid1">1</a>]. For patients with persistent parasitemia (≥1 month), we administer treatment.</p><p class="headingAnchor" id="H1203365673"><span class="h4">Mild to moderate disease</span><span class="headingEndMark"> — </span>Mild to moderate babesiosis typically occurs in immunocompetent patients and is associated with parasitemia &lt;4 percent; it does not require hospital admission. (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis", section on 'Mild to moderate disease'</a>.)</p><p>Treatment with antimicrobial therapy is warranted for symptomatic individuals with mild to moderate <em>B. microti</em> infection confirmed by microscopy or polymerase chain reaction (PCR). The preferred regimen consists of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> given orally; <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> given orally is an alternative option [<a href="#rid1">1,2,5</a>]. The duration of therapy is 7 to 10 days; dosing is summarized in the table (<a class="graphic graphic_table graphicRef114688" href="/d/graphic/114688.html" rel="external">table 1</a>).</p><p>This approach is supported by a randomized trial in which 58 adults with non–life-threatening babesiosis were treated with a seven day course of either <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (40 patients) or <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (18 patients) [<a href="#rid6">6</a>]. Three months after completion of therapy, no parasites were seen by microscopy and no <em>Babesia</em> deoxyribonucleic acid (DNA) was detected by endpoint PCR in any patient. Atovaquone plus azithromycin was associated with less frequent adverse effects than clindamycin plus quinine (15 versus 72 percent, respectively). Adverse effects associated with atovaquone plus azithromycin include diarrhea and rash. Adverse effects associated with clindamycin plus quinine include diarrhea, rash, and symptoms of cinchonism (eg, tinnitus, decreased hearing, and vertigo), prompting dose reduction or drug discontinuation in one-third of cases. Both azithromycin and quinine can produce QT prolongation and cardiac arrhythmias [<a href="#rid7">7</a>].</p><p>Symptoms usually begin to abate within 48 hours after initiating antimicrobial therapy and resolve within one to two weeks [<a href="#rid4">4</a>]. Fatigue may persist but generally resolves within three months after initiating therapy. Patients with mild to moderate babesiosis seldom experience complications. Data regarding the timeframe for resolution of anemia and other laboratory parameters are limited. No follow-up is required unless the patient has persistent or recurrent symptoms. </p><p>In immunocompetent patients who complete treatment for babesiosis and subsequently undergo splenectomy or become immunocompromised, an unexplained febrile illness should raise suspicion of babesiosis and prompt immediate clinical evaluation.</p><p class="headingAnchor" id="H838659983"><span class="h4">Severe disease</span><span class="headingEndMark"> — </span>Severe babesiosis is associated with parasitemia ≥4 percent (although it can occur with parasitemia &lt;4 percent) and may lead to complications and/or persistent or relapsing disease [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis", section on 'Severe disease'</a>.)</p><p>Management of severe babesiosis consists of hospitalization, antimicrobial therapy, and, in some cases, red blood cell exchange transfusion.</p><p class="headingAnchor" id="H772674862"><span class="h5">Antimicrobial therapy</span><span class="headingEndMark"> — </span>For treatment of severe babesiosis, we favor intravenous (IV) <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a>; IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> is an alternative option (<a class="graphic graphic_table graphicRef114688" href="/d/graphic/114688.html" rel="external">table 1</a>) [<a href="#rid1">1,2,10</a>]. IV therapy can be replaced with oral therapy once symptoms have abated and parasitemia has been reduced. </p><p>The usual duration of therapy for immunocompetent patients with severe babesiosis is 7 to 10 days. The duration of therapy should be extended if parasitemia and symptoms, such as fever, persist. Such cases are uncommon in immunocompetent patients. Cessation of therapy should be guided by parasite clearance and clinical improvement. Fatigue may persist for months following completion of a standard course of antibiotic therapy, but fatigue alone does not warrant extension of therapy [<a href="#rid11">11</a>]. </p><p>There have been no prospective trials to compare the efficacy of antimicrobials in patients with severe babesiosis. In a retrospective study including 40 patients hospitalized for severe babesiosis and treated with a combination of <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, all but one patient fully recovered [<a href="#rid10">10</a>].</p><p>The optimal approach for treatment of severe babesiosis when the above regimens have been ineffective is uncertain. Alternative options (based on case reports) include IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> or a three-drug regimen consisting of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, atovaquone, and clindamycin [<a href="#rid3">3,5,12</a>].</p><p><a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">Chloroquine</a> is not effective for treatment of human <em>B. microti</em> infection. In animal models, other antimalarials (such as <a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">primaquine</a>, quinacrine, <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a>, pyrimethamine-sulfadoxine, and <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>) are also ineffective [<a href="#rid13">13,14</a>]. Studies in highly immunocompromised mice have described drugs for treatment of <em>B. microti</em> infection including <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>, <a class="drug drug_general" data-topicid="118521" href="/d/drug information/118521.html" rel="external">tafenoquine</a>, and the combination of an endochin-like quinolone plus <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> [<a href="#rid15">15-19</a>].</p><p><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> and <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> are known to prolong the QT interval; however, a retrospective study including 163 patients hospitalized for babesiosis found no association between use of these antibiotics and QT interval prolongation [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H368575823"><span class="h5">Exchange transfusion</span><span class="headingEndMark"> — </span>Red blood cell exchange transfusion (ie, removing patient red blood cells and replacing with allogeneic red blood cells; either partially or completely) may be warranted for patients with high-grade parasitemia (&gt;10 percent) and/or who one or more of the following: severe hemolytic anemia or severe organ (pulmonary, renal or hepatic) compromise [<a href="#rid1">1,3,5,21</a>].</p><p>This approach is based on a limited number of case reports and case series [<a href="#rid8">8,22-24</a>]. There have been no prospective systematic studies on this therapeutic modality, nor are there data on the benefit and optimal use of red blood cell exchange versus whole blood or plasma exchange. </p><p>Exchange transfusion reduces parasitemia and corrects anemia [<a href="#rid22">22,25</a>].</p><p>Use of exchange transfusion early in the course of severe <em>B. microti</em> infection has been advocated on the basis that prompt reduction in parasitemia reduces the risk of complications [<a href="#rid8">8,12,23,24,26-28</a>]. In Europe, mortality from <em>B. divergens</em> infection in immunocompromised patients has markedly decreased with improved adjunctive therapy including prompt use of exchange transfusion [<a href="#rid29">29,30</a>]. Repeat exchange transfusion may be considered when parasitemia remains elevated following initial exchange transfusion [<a href="#rid12">12,31</a>].</p><p>Two retrospective studies have examined the relationship between parasitemia and clinical outcome of <em>B. microti</em> infection. In one study including 19 patients who underwent red blood cell exchange, higher baseline parasitemia was associated with a longer hospital stay but had no impact on one-month mortality [<a href="#rid23">23</a>]. In another study including 91 patients hospitalized for babesiosis, a significant association between parasitemia and disease severity was observed [<a href="#rid24">24</a>]. These data support use of parasitemia &gt;10 percent and/or end organ impairment as the criteria for consideration of exchange transfusion in severe babesiosis. Successful management of three patients with parasitemia &gt;10 percent without exchange transfusion has been described [<a href="#rid32">32</a>].</p><p>Management of exchange transfusion should be handled in close consultation with experts in hematology and apheresis [<a href="#rid8">8,23,26,27</a>]. The efficacy of plasma exchange compared with red blood cell exchange has not been evaluated. Exchange transfusion can be performed manually or using apheresis equipment [<a href="#rid28">28</a>]. Red blood cell transfusion is indicated for patients who do not warrant exchange transfusion but have hemoglobin level ≤7 g/dL or symptoms attributable to anemia (eg, hemodynamic compromise, dyspnea). (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a> and  <a class="medical medical_review" href="/d/html/5910.html" rel="external">"Red blood cell transfusion in infants and children: Indications"</a>.)</p><p class="headingAnchor" id="H1068464983"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>For immunocompetent patients, we suggest monitoring parasitemia using peripheral blood smears during treatment of acute illness [<a href="#rid1">1</a>]. Monitoring parasitemia once symptoms have resolved is of limited value because immunocompetent patients almost never relapse. (See <a class="local">'Mild to moderate disease'</a> above and <a class="local">'Severe disease'</a> below.) </p><p class="headingAnchor" id="H2670357545"><span class="h4">Recurrent infection</span><span class="headingEndMark"> — </span>Management of reinfection in immunocompetent patients consists of a repeat standard course of <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, unless antimicrobial resistance is documented [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H2308038272"><span class="h3">Pregnant patients</span><span class="headingEndMark"> — </span>Treatment of pregnant patients with babesiosis should consist of <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> rather than <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a>. A case of successful treatment of <em>B. microti</em> infection in pregnancy with clindamycin plus quinine has been reported [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H3574064374"><span class="h3">Patients with splenic rupture</span><span class="headingEndMark"> — </span>For patients with splenic rupture who are hemodynamically unstable or deteriorate rapidly, emergent splenectomy is warranted. For patients who are hemodynamically stable with persistent hemorrhage, splenic artery embolization may be considered [<a href="#rid35">35,36</a>]. A nonsurgical approach is preferable, because splenectomy may impede parasite clearance and predispose to increased severity of subsequent infections.</p><p class="headingAnchor" id="H3522259590"><span class="h2">Immunocompromised patients</span></p><p class="headingAnchor" id="H3049553791"><span class="h3">Acute infection</span></p><p class="headingAnchor" id="H3523568762"><span class="h4">Mild to moderate disease</span><span class="headingEndMark"> — </span>Immunocompromised patients with mild to moderate <em>B. microti</em> infection may be treated on an outpatient basis with close monitoring. Antimicrobial therapy consists of oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 to 1000 mg orally per day) plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (750 mg orally twice daily).</p><p>Laboratory parameters (complete blood count and parasitemia) should be monitored every two to three days until the blood count normalizes and parasites are no longer seen on smear.</p><p>The duration of antimicrobial therapy is discussed below. (See <a class="local">'Duration of antimicrobial therapy'</a> below.)</p><p class="headingAnchor" id="H1702444667"><span class="h4">Severe disease</span><span class="headingEndMark"> — </span>Immunocompromised patients with severe disease should be managed with hospital admission for administration of antimicrobial therapy and monitoring; exchange transfusion is warranted in some circumstances. (See <a class="local">'Exchange transfusion'</a> above.)</p><p>Antimicrobial therapy for immunocompromised patients with severe disease consists of IV <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg/day) plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (750 mg twice daily). Once symptoms have abated and parasitemia has diminished, azithromycin can be given orally (500 mg/day), and oral atovaquone (750 mg twice daily) should be continued. Higher doses of oral azithromycin (up to 1000 mg per day) have been used and may accelerate parasite clearance [<a href="#rid37">37-39</a>].</p><p>Laboratory parameters (complete blood count and parasitemia) should be monitored daily until parasitemia is &lt;4 percent and symptoms have abated; thereafter, parasitemia should be monitored every two to three days until parasites are no longer seen on smear. Renal function and hepatic function should be closely monitored until they become normal. (See <a class="local">'Monitoring'</a> below.)</p><p>The duration of antimicrobial therapy is discussed below. (See <a class="local">'Duration of antimicrobial therapy'</a> below.)</p><p>An alternative antimicrobial regimen is IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (adult dose 600 mg IV every six hours) plus oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (adult dose 650 mg orally every eight hours), although quinine is often poorly tolerated. IV clindamycin can be replaced with oral clindamycin once symptoms have abated and parasitemia has been reduced.</p><p class="headingAnchor" id="H2023665722"><span class="h4">Duration of antimicrobial therapy</span><span class="headingEndMark"> — </span>The duration of therapy in immunocompromised patients depends upon the risk of relapse [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute disease with <strong>low risk </strong>of relapse typically occurs in patients with one of the following conditions: age &gt;50 years, asplenia, malignancy, and human immunodeficiency virus (HIV) infection without acquired immunodeficiency syndrome (AIDS). (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis", section on 'Severe disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe acute disease with<strong> high risk </strong>of relapse typically occurs in patients with impaired <em>Babesia</em> antibody production [<a href="#rid40">40</a>]. These include patients with B cell lymphoma or other conditions treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (or other B cell-depleting agents), patients with malignancy who also are asplenic, patients with solid organ or stem cell transplantation, and patients with HIV/AIDS. Relapse usually occurs<strong> </strong>within a few days or a week after discontinuation of antibiotics, but the interval can be longer. (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis", section on 'Relapse'</a>.)</p><p></p><p class="headingAnchor" id="H2288695888"><span class="h5">Low risk of relapse</span><span class="headingEndMark"> — </span>For patients at low risk of relapse, the duration of therapy is at least 7 to 10 days; in some circumstances, a longer duration of therapy may be needed. The total duration of therapy depends on individual clinical circumstances and should be tailored to resolution of symptoms and laboratory parameters (complete blood count and parasitemia &lt;4 percent). If low-grade parasitemia persists following completion of therapy, patients should be monitored with blood smear twice weekly until <em>Babesia</em> parasites are no longer observed.</p><p class="headingAnchor" id="H2815754760"><span class="h5">High risk of relapse</span><span class="headingEndMark"> — </span>For patients at high risk of relapse, antibiotics should be administered for at least six consecutive weeks and should be discontinued only after <em>Babesia</em> parasites have no longer been detected on blood smear for two consecutive weeks. This approach is supported by a retrospective case-control study that included 14 case patients in whom parasites persisted on blood smear despite repeated courses of antimicrobial therapy and 46 control patients in whom parasitemia cleared and symptoms resolved within one month following a single course of standard antimicrobial therapy. The case patients required treatment for ≥6 weeks to achieve cure, including 2 weeks during which parasites were no longer detected on blood smear [<a href="#rid40">40</a>]. However, this approach has been unsuccessful in a few cases [<a href="#rid37">37,39</a>].</p><p>PCR is more sensitive than blood smear but typically remains positive for months after clinical cure (complete resolution of symptoms with no recurrence) [<a href="#rid11">11</a>]. DNA may persist in the blood as long as 27 months in the setting of immunosuppression [<a href="#rid11">11,41</a>]. Thus, for immunocompromised patients at high risk of relapse, the benefit of administering antimicrobial therapy until PCR becomes negative should be balanced against the risks and costs associated with unnecessarily prolonged antimicrobial therapy. Despite the sensitivity provided by real-time PCR, cases of relapse following apparent parasite clearance (as assessed by both blood smear and PCR) have been described [<a href="#rid42">42-44</a>].</p><p>Clinicians should advise immunocompromised patients to seek immediate medical attention if they develop fever or other symptoms consistent with babesiosis following apparent successful antibiotic therapy. If fever and/or other symptoms consistent with babesiosis recur within a few days or weeks of initial treatment, a blood smear should be obtained. (See  <a class="medical medical_review" href="/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis", section on 'Microscopy'</a>.)</p><p class="headingAnchor" id="H853161608"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>For immunocompromised patients, we suggest monitoring parasitemia using peripheral blood smears during treatment of acute illness and after resolution of symptoms, until blood smears are negative [<a href="#rid1">1</a>]. Additional details regarding use of monitoring to guide duration of therapy depend on the likelihood of relapse, as discussed above. (See <a class="local">'Duration of antimicrobial therapy'</a> above.)</p><p class="headingAnchor" id="H1007099626"><span class="h3">Relapse</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – Management of relapse consists of a repeat course of antibiotic therapy. In addition, the level of immunosuppression should be reduced if feasible [<a href="#rid37">37,41</a>].</p><p></p><p class="bulletIndent1">The antibiotic regimen used for the repeat course can be the same as that used for the initial course (usually <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a>). The duration of therapy is as described for immunocompromised patients with high risk of relapse. (See <a class="local">'High risk of relapse'</a> above.)</p><p></p><p class="bulletIndent1">Treatment failure has been observed with <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and with <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>. Antimicrobial resistance has been documented for atovaquone, azithromycin, and clindamycin in immunocompromised hosts [<a href="#rid38">38-40,42,45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> – For patients who do not appear to respond well to <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, therapy may be switched to <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>. Since quinine often is poorly tolerated, an acceptable alternative regimen consists of azithromycin, atovaquone, and clindamycin.</p><p></p><p class="bulletIndent1">Other antibiotic combinations have been used successfully, but there have been few reports of their use. These include <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> plus <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (with or without <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), <a class="drug drug_general" data-topicid="8704" href="/d/drug information/8704.html" rel="external">atovaquone-proguanil</a> plus azithromycin, atovaquone plus azithromycin plus clindamycin plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>, and azithromycin plus quinine [<a href="#rid1">1,5,40,47-50</a>].</p><p></p><p class="bulletIndent1">Successful use of <a class="drug drug_general" data-topicid="118521" href="/d/drug information/118521.html" rel="external">tafenoquine</a> (300 mg on day 1, 150 mg on days 2 and 3, and 300 mg weekly for 9 weeks) for treatment of relapse in an immunocompromised patient has been described in a case report [<a href="#rid45">45</a>]. Blood smears were negative after one week and PCR was negative after three weeks of tafenoquine. G6PD status should be assessed before use of tafenoquine; the drug is contraindicated in the setting of G6PD deficiency. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H200754606"><span class="h2">Co-infection with tick-transmitted pathogens</span><span class="headingEndMark"> — </span>In the United States, <em>Ixodes scapularis</em> ticks transmit three major human pathogens: <em>Borrelia burgdorferi</em> (Lyme disease), <em>Anaplasma phagocytophilum</em> (anaplasmosis), and <em>Babesia microti</em> (babesiosis). They are also capable of transmitting other pathogens including <em>Borrelia mayonii</em> (Lyme disease), <em>Borrelia miyamotoi</em> (hard tick relapsing fever), Powassan virus (Powassan virus disease), and <em>Ehrlichia muris eauclairensis </em>(ehrlichiosis).</p><p>Human coinfection rates differ with respect to pathogen and geography, as well as research methods including case definitions. Approximately half of patients with babesiosis are coinfected with Lyme disease, and most of these patients present with an erythema migrans rash [<a href="#rid51">51-56</a>]. The frequency of coinfection with babesiosis and anaplasmosis is much lower [<a href="#rid53">53,55</a>].</p><p>Patients with known or suspected babesiosis should be evaluated carefully for erythema migrans rash; in addition, testing for Lyme disease and anaplasmosis is warranted. In addition, in settings where Lyme disease and anaplasmosis are endemic, we suggest empiric treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (for coinfection with Lyme disease and/or anaplasmosis), pending definitive diagnostic data regarding coinfection. For patients treated for babesiosis whose symptoms worsen or do not resolve within the first 48 hours of therapy, we initiate empiric doxycycline therapy, pending further diagnostic data. (See  <a class="medical medical_review" href="/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7914.html" rel="external">"Diagnosis of Lyme disease"</a> and  <a class="medical medical_review" href="/d/html/7907.html" rel="external">"Human ehrlichiosis and anaplasmosis"</a>.)</p><p class="headingAnchor" id="H3508690631"><span class="h1">TREATMENT OF INFECTION DUE TO OTHER SPECIES</span></p><p class="headingAnchor" id="H1172528763"><span class="h2">B. divergens</span><span class="headingEndMark"> — </span>Clinical information about treatment of <em>B. divergens</em> infections is limited to case reports. Infection due to <em>B. divergens</em> frequently causes fulminant illness; therefore, illness attributed to this species should be considered a medical emergency and treated with a combination of antimicrobial therapy and exchange transfusion.</p><p>The antimicrobial regimen of choice has been intravenous (IV) <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (in adults: 600 mg IV every 6 to 8 hours; in children: 7 to 10 mg/kg IV every 6 to 8 hours [maximum 600 mg/dose]) combined with oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (in adults: 650 mg orally every 8 hours; in children: 8 mg/kg orally every 8 hours [maximum 650 mg/dose]). The duration of therapy is at least 7 to 10 days [<a href="#rid1">1,57</a>]. Other regimens have included clindamycin monotherapy and, in one case, IV <a class="drug drug_general" data-topicid="9752" href="/d/drug information/9752.html" rel="external">pentamidine</a> plus oral <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid29">29,58</a>].</p><p>Following clearance of <em>B. divergens</em> parasitemia, anemia that is severe enough to warrant transfusion of red blood cells may persist for &gt;1 month [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3091412244"><span class="h2">B. divergens-like organisms</span><span class="headingEndMark"> — </span>Clinical experience with treatment of infection due to <em>B. divergens</em>–like organisms is limited to case reports [<a href="#rid59">59-63</a>]. Oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> or <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> (650 mg three times daily) plus IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (650 to 900 mg three times daily or 1200 mg twice daily) have been used. Quinidine is no longer available in the United States.</p><p class="headingAnchor" id="H3041932699"><span class="h2">B. duncani</span><span class="headingEndMark"> — </span>Clinical experience with treatment of infection due to <em>B. duncani</em> is limited [<a href="#rid64">64-68</a>]. All reported cases of <em>B. duncani</em> infection have been treated with a course of <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (600 mg three to four times per day or 1200 mg twice daily) plus <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> or <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a> (600 to 650 mg three times daily). Quinidine is no longer available in the United States. In one case, symptoms relapsed and were successfully treated with IV clindamycin (1200 mg twice daily). In severe cases, red blood cell exchange transfusion and hemodialysis were instituted.</p><p class="headingAnchor" id="H3852125098"><span class="h2">B. venatorum</span><span class="headingEndMark"> — </span>Clinical experience with treatment of infection due to <em>B. venatorum</em> is derived from cases in Europe and China [<a href="#rid69">69-73</a>]. The European cases were treated with one or two antibiotic regimens. A mild case was cured with IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (600 mg three times daily) [<a href="#rid70">70</a>]. A more severe case was successfully treated with IV clindamycin (600 mg three times daily) plus oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> (650 mg three times daily). Hemolytic anemia required the transfusion of 11 units of packed red blood cells [<a href="#rid70">70</a>]. Another severe case complicated by acute renal failure was successfully treated with oral clindamycin (600 mg three times daily) plus oral quinine (500 mg three times daily) [<a href="#rid71">71</a>]. A fourth case had received <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> prior to the diagnosis of babesiosis and relapsed following a course of oral clindamycin plus oral quinine. Because of intolerance to quinine, the second course consisted of oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (750 mg twice daily) plus oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg once daily). Atovaquone was continued for 5 months to treat persistence of parasites in the absence of symptoms [<a href="#rid69">69</a>].</p><p>A child from northwestern China experienced severe <em>B. venatorum</em> disease but was cured with a course of oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (20 mg/kg twice daily) plus oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (12 mg/kg once daily) [<a href="#rid72">72</a>]. In a case series of <em>B. venatorum</em> infection from northeastern China, 4 of 48 patients were treated with <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> alone, whereas the other cases resolved despite receiving antibiotics that are not commonly used for babesiosis.</p><p class="headingAnchor" id="H2141689759"><span class="h2">B. crassa-like organisms</span><span class="headingEndMark"> — </span>A case series noted that <em>B. crassa</em>-like organisms that typically infect sheep can induce a mild to moderate illness in immunocompetent humans [<a href="#rid74">74</a>]. None of the 31 patients were treated with one of the antimicrobial regimens recommended for babesiosis caused by <em>B. microti</em>. Three patients received <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> alone. None of the patients died.</p><p class="headingAnchor" id="H1900095367"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prevention of babesiosis consists of personal protective measures that minimize exposure to ticks [<a href="#rid3">3,5</a>]. Patients at risk of severe babesiosis (asplenic individuals and other immunocompromised individuals) should avoid <em>Babesia</em> endemic areas during the tick transmission season (late spring, summer, and early fall), particularly those where ticks abound. (See  <a class="medical medical_review" href="/d/html/7895.html" rel="external">"Prevention of Lyme disease", section on 'Personal protection'</a>.)</p><p>If it is not possible to avoid such exposure, the risk of babesiosis can be reduced by wearing long pants and long-sleeved shirts, applying tick repellants to skin (such as N,N-diethyl-metatoluamide [DEET]) and clothing (<a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a>), and performing tick checks after possible exposure. (See  <a class="medical medical_review" href="/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p>Environmental management also may be helpful; interventions include keeping lawns mown, placing stone or wood chip barriers between lawn and woods, spraying property with an acaricide, placing cotton balls impregnated with <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> in yards, and culling the local deer herd.</p><p>There is no antibiotic regimen for prophylaxis of babesiosis. There is no vaccine available for human use.</p><p class="headingAnchor" id="H1918204859"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111579.html" rel="external">"Society guideline links: Tick-borne infections (Lyme disease, ehrlichiosis, anaplasmosis, babesiosis, and Rocky Mountain spotted fever)"</a>.)</p><p class="headingAnchor" id="H3427444370"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate illness</strong> – For immunocompetent individuals with mild to moderate <em>Babesia microti</em> infection, we suggest treating with oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment is administered orally for 7 to 10 days; dosing is summarized in the table (<a class="graphic graphic_table graphicRef114688" href="/d/graphic/114688.html" rel="external">table 1</a>). For individuals with asymptomatic <em>B. microti</em> infection, we suggest no antimicrobial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild to moderate disease'</a> above and <a class="local">'Asymptomatic infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe illness</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Antimicrobial therapy</strong> – For immunocompetent individuals with severe <em>B. microti</em> infection, we suggest treatment with intravenous (IV) <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> is an alternative regimen (<a class="graphic graphic_table graphicRef114688" href="/d/graphic/114688.html" rel="external">table 1</a>). (See <a class="local">'Severe disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Exchange transfusion</strong> – Patients with severe <em>B. microti</em> infection may warrant exchange transfusion. We suggest exchange transfusion for patients with high-grade parasitemia (&gt;10 percent), severe hemolysis (hemoglobin &lt;10 g/dL), or organ (pulmonary, renal, or liver) impairment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Exchange transfusion'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Duration of therapy</strong> – The usual duration of antimicrobial therapy for immunocompetent patients with severe <em>B. microti</em> infection is 7 to 10 days; in some circumstances, a longer duration of therapy may be needed. IV therapy can be replaced with oral therapy once symptoms have abated and parasitemia has been reduced. (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild to moderate illness</strong> – For immunocompromised patients with mild to moderate <em>B. microti</em> infection, we suggest initial treatment with oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) as well as close monitoring. For patients who do not improve within 48 hours, we hospitalize and treat as for severe illness. (See <a class="local">'Mild to moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe illness</strong> – Immunocompromised patients with severe <em>B. microti</em> infection should be managed with hospitalization and IV therapy. We suggest treatment with IV <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus oral <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> plus oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a> is an alternative regimen. (See <a class="local">'Severe disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – The duration of therapy for <em>B. microti</em> infection in immunocompromised patients depends on the risk of relapse (see <a class="local">'Duration of antimicrobial therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with one of the following conditions typically have low risk of relapse: age &gt;50 years, asplenia, malignancy, and HIV infection without AIDS. In such patients, the duration of therapy is at least 7 to 10 days; it should be tailored to the resolution of symptoms and laboratory parameters. If low-grade parasitemia on blood smear persists following completion of therapy and resolution of symptoms, patients should be monitored with blood smear twice weekly until no <em>Babesia</em> are observed. (See <a class="local">'Low risk of relapse'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with impaired <em>Babesia</em> antibody production typically have high risk of relapse. These include patients with B cell lymphoma or other conditions treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (or other B cell-depleting agent), patients with malignancy who also are asplenic, patients with solid organ or stem cell transplantation, and patients with HIV/AIDS. In such patients, the duration of therapy is at least six weeks, including two final consecutive weeks during which <em>Babesia</em> parasites are no longer seen on blood smear. (See <a class="local">'High risk of relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse</strong> – Management of relaps<em>ed B. microti</em> infection consists of a repeat course of antibiotic therapy. The antibiotic regimen used for the repeat course can be the same as that used for the initial course (usually <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a>). The duration of therapy is the same as the duration for immunocompromised patients with high risk of relapse. (See <a class="local">'Relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coinfection with tick-transmitted pathogens</strong> – For patients with known or suspected babesiosis, we suggest empiric treatment with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (for coinfection with Lyme disease and/or anaplasmosis), pending definitive diagnostic data regarding coinfection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Co-infection with tick-transmitted pathogens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Babesia divergens</em></strong> – <em>B. divergens</em> frequently causes fulminant illness and should be considered a medical emergency. Management consists of antimicrobial therapy and exchange transfusion. We suggest treatment with IV <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> and oral <a class="drug drug_general" data-topicid="9847" href="/d/drug information/9847.html" rel="external">quinine</a>; the duration of therapy is at least 7 to 10 days. (See <a class="local">'B. divergens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Prevention of babesiosis consists of personal protective measures that minimize exposure to ticks. (See <a class="local">'Prevention'</a> above.) </p><p></p><p class="headingAnchor" id="H1620797128"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jeffrey A Gelfand, MD, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis 2021; 72:185.</a></li><li><a class="nounderline abstract_t">Corrigendum to: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis. Clin Infect Dis 2021; 73:172.</a></li><li><a class="nounderline abstract_t">Vannier E, Krause PJ. Human babesiosis. N Engl J Med 2012; 366:2397.</a></li><li><a class="nounderline abstract_t">Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am 2015; 29:357.</a></li><li><a class="nounderline abstract_t">Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review. JAMA 2016; 315:1767.</a></li><li><a class="nounderline abstract_t">Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343:1454.</a></li><li><a class="nounderline abstract_t">Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.</a></li><li><a class="nounderline abstract_t">Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001; 32:1117.</a></li><li><a class="nounderline abstract_t">White DJ, Talarico J, Chang HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158:2149.</a></li><li><a class="nounderline abstract_t">Kletsova EA, Spitzer ED, Fries BC, Marcos LA. Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone. Ann Clin Microbiol Antimicrob 2017; 16:26.</a></li><li><a class="nounderline abstract_t">Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998; 339:160.</a></li><li><a class="nounderline abstract_t">Li Y, Stanley S, Villalba JA, et al. Case Report: Overwhelming Babesia Parasitemia Successfully Treated Promptly With RBC Apheresis and Triple Therapy With Clindamycin, Azithromycin, and Atovaquone. Open Forum Infect Dis 2020; 7:ofaa448.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Clindamycin and quinine treatment for Babesia microti infections. MMWR Morb Mortal Wkly Rep 1983; 32:65.</a></li><li><a class="nounderline abstract_t">Miller LH, Neva FA, Gill F. Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters. Ann Intern Med 1978; 88:200.</a></li><li><a class="nounderline abstract_t">Tuvshintulga B, Vannier E, Tayebwa DS, et al. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. J Infect Dis 2020; 222:1027.</a></li><li><a class="nounderline abstract_t">Lawres LA, Garg A, Kumar V, et al. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone. J Exp Med 2016; 213:1307.</a></li><li><a class="nounderline abstract_t">Mordue DG, Wormser GP. Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection? J Infect Dis 2019; 220:442.</a></li><li><a class="nounderline abstract_t">Tuvshintulga B, Sivakumar T, Nugraha AB, et al. Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts. J Infect Dis 2022; 225:238.</a></li><li><a class="nounderline abstract_t">Vannier E, Gelfand JA. Clofazimine for Babesiosis: Preclinical Data Support a Clinical Trial. J Infect Dis 2022; 225:187.</a></li><li><a class="nounderline abstract_t">Spichler-Moffarah A, Ong E, O'Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clin Infect Dis 2023; 76:e1385.</a></li><li><a class="nounderline abstract_t">Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019; 34:171.</a></li><li><a class="nounderline abstract_t">Spaete J, Patrozou E, Rich JD, Sweeney JD. Red cell exchange transfusion for babesiosis in Rhode Island. J Clin Apher 2009; 24:97.</a></li><li><a class="nounderline abstract_t">Nixon CP, Park S, Nixon CE, et al. Adjunctive treatment of clinically severe babesiosis with red blood cell exchange: a case series of nineteen patients. Transfusion 2019; 59:2629.</a></li><li><a class="nounderline abstract_t">O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. J Clin Apher 2021; 36:127.</a></li><li><a class="nounderline abstract_t">Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? J Clin Apher 2016; 31:454.</a></li><li><a class="nounderline abstract_t">Stowell CP, Gelfand JA, Shepard JA, Kratz A. Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. N Engl J Med 2007; 356:2313.</a></li><li><a class="nounderline abstract_t">Jacoby GA, Hunt JV, Kosinski KS, et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med 1980; 303:1098.</a></li><li><a class="nounderline abstract_t">Yager PH, Luginbuhl LM, Dekker JP. Case records of the Massachusetts General Hospital. Case 6-2014. A 35-day-old boy with fever, vomiting, mottled skin, and severe anemia. N Engl J Med 2014; 370:753.</a></li><li><a class="nounderline abstract_t">Zintl A, Mulcahy G, Skerrett HE, et al. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 2003; 16:622.</a></li><li><a class="nounderline abstract_t">Hildebrandt A, Gray JS, Hunfeld KP. Human babesiosis in Europe: what clinicians need to know. Infection 2013; 41:1057.</a></li><li><a class="nounderline abstract_t">Radcliffe C, Krause PJ, Grant M. Repeat exchange transfusion for treatment of severe babesiosis. Transfus Apher Sci 2019; 58:638.</a></li><li><a class="nounderline abstract_t">Cervera-Hernandez ME, Zaidi N, Sweeney JD. Heavy parasitemia in babesiosis treated without adjunctive red cell exchange. Transfus Apher Sci 2019; 58:439.</a></li><li><a class="nounderline abstract_t">Ho J, Carey E, Carey DE, Krause PJ. Recurrence of Human Babesiosis Caused by Reinfection. Emerg Infect Dis 2021; 27.</a></li><li><a class="nounderline abstract_t">Feder HM Jr, Lawlor M, Krause PJ. Babesiosis in pregnancy. N Engl J Med 2003; 349:195.</a></li><li><a class="nounderline abstract_t">El Khoury MY, Gandhi R, Dandache P, et al. Non-surgical management of spontaneous splenic rupture due to Babesia microti infection. Ticks Tick Borne Dis 2011; 2:235.</a></li><li><a class="nounderline abstract_t">Semel ME, Tavakkolizadeh A, Gates JD. Babesiosis in the immediate postoperative period after splenectomy for trauma. Surg Infect (Larchmt) 2009; 10:553.</a></li><li><a class="nounderline abstract_t">Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis 2010; 50:381.</a></li><li><a class="nounderline abstract_t">Lemieux JE, Tran AD, Freimark L, et al. A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse. Nat Microbiol 2016; 1:16079.</a></li><li><a class="nounderline abstract_t">Simon MS, Westblade LF, Dziedziech A, et al. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clin Infect Dis 2017; 65:1222.</a></li><li><a class="nounderline abstract_t">Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370.</a></li><li><a class="nounderline abstract_t">Raffalli J, Wormser GP. Persistence of babesiosis for &gt;2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis 2016; 85:231.</a></li><li><a class="nounderline abstract_t">Rosenblatt J, Leung A, Baneman E, et al. Relapsed Babesia microti Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Open Forum Infect Dis 2021; 8:ofab323.</a></li><li><a class="nounderline abstract_t">Marcos LA, Leung A, Kirkman L, Wormser GP. Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone. IDCases 2022; 27:e01460.</a></li><li><a class="nounderline abstract_t">Prasad PJ, Wormser GP. Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Babesia microti Infection in an Immunocompromised Patient. Pathogens 2022; 11.</a></li><li><a class="nounderline abstract_t">Rogers R, Krause PJ, Norris AM, et al. Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine. Clin Infect Dis 2023; 76:741.</a></li><li><a class="nounderline abstract_t">Holbrook NR, Klontz EH, Adams GC, et al. Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis. Open Forum Infect Dis 2023; 10:ofad097.</a></li><li><a class="nounderline abstract_t">Shih CM, Wang CC. Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans. Am J Trop Med Hyg 1998; 59:509.</a></li><li><a class="nounderline abstract_t">Falagas ME, Klempner MS. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin Infect Dis 1996; 22:809.</a></li><li><a class="nounderline abstract_t">Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis 2007; 45:1588.</a></li><li><a class="nounderline abstract_t">Shaio MF, Yang KD. Response of babesiosis to a combined regimen of quinine and azithromycin. Trans R Soc Trop Med Hyg 1997; 91:214.</a></li><li><a class="nounderline abstract_t">Meldrum SC, Birkhead GS, White DJ, et al. Human babesiosis in New York State: an epidemiological description of 136 cases. Clin Infect Dis 1992; 15:1019.</a></li><li><a class="nounderline abstract_t">Krause PJ, Telford SR 3rd, Spielman A, et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 1996; 275:1657.</a></li><li><a class="nounderline abstract_t">Krause PJ, McKay K, Thompson CA, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002; 34:1184.</a></li><li><a class="nounderline abstract_t">Kowalski TJ, Jobe DA, Dolan EC, et al. The Emergence of Clinically Relevant Babesiosis in Southwestern Wisconsin. WMJ 2015; 114:152.</a></li><li><a class="nounderline abstract_t">Menis M, Forshee RA, Kumar S, et al. Babesiosis Occurrence among the Elderly in the United States, as Recorded in Large Medicare Databases during 2006-2013. PLoS One 2015; 10:e0140332.</a></li><li><a class="nounderline abstract_t">Mareedu N, Schotthoefer AM, Tompkins J, et al. Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis. Am J Trop Med Hyg 2017; 97:1218.</a></li><li><a class="nounderline abstract_t">Ord RL, Lobo CA. Human Babesiosis: Pathogens, Prevalence, Diagnosis and Treatment. Curr Clin Microbiol Rep 2015; 2:173.</a></li><li><a class="nounderline abstract_t">Raoult D, Soulayrol L, Toga B, et al. Babesiosis, pentamidine, and cotrimoxazole. Ann Intern Med 1987; 107:944.</a></li><li><a class="nounderline abstract_t">Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med 2002; 347:697.</a></li><li><a class="nounderline abstract_t">Herwaldt B, Persing DH, Précigout EA, et al. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 1996; 124:643.</a></li><li><a class="nounderline abstract_t">Herwaldt BL, de Bruyn G, Pieniazek NJ, et al. Babesia divergens-like infection, Washington State. Emerg Infect Dis 2004; 10:622.</a></li><li><a class="nounderline abstract_t">Burgess MJ, Rosenbaum ER, Pritt BS, et al. Possible Transfusion-Transmitted Babesia divergens-like/MO-1 Infection in an Arkansas Patient. Clin Infect Dis 2017; 64:1622.</a></li><li><a class="nounderline abstract_t">Herc E, Pritt B, Huizenga T, et al. Probable Locally Acquired Babesia divergens-Like Infection in Woman, Michigan, USA. Emerg Infect Dis 2018; 24.</a></li><li><a class="nounderline abstract_t">Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med 1995; 332:298.</a></li><li><a class="nounderline abstract_t">Quick RE, Herwaldt BL, Thomford JW, et al. Babesiosis in Washington State: a new species of Babesia? Ann Intern Med 1993; 119:284.</a></li><li><a class="nounderline abstract_t">Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997; 175:1259.</a></li><li><a class="nounderline abstract_t">Kjemtrup AM, Lee B, Fritz CL, et al. Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California. Transfusion 2002; 42:1482.</a></li><li><a class="nounderline abstract_t">Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012; 52:1517.</a></li><li><a class="nounderline abstract_t">Häselbarth K, Tenter AM, Brade V, et al. First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol 2007; 297:197.</a></li><li><a class="nounderline abstract_t">Herwaldt BL, Cacciò S, Gherlinzoni F, et al. Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis 2003; 9:942.</a></li><li><a class="nounderline abstract_t">Blum S, Gattringer R, Haschke E, et al. The case: hemolysis and acute renal failure. Babesiosis. Kidney Int 2011; 80:681.</a></li><li><a class="nounderline abstract_t">Sun Y, Li SG, Jiang JF, et al. Babesia venatorum Infection in Child, China. Emerg Infect Dis 2014; 20:896.</a></li><li><a class="nounderline abstract_t">Jiang JF, Zheng YC, Jiang RR, et al. Epidemiological, clinical, and laboratory characteristics of 48 cases of "Babesia venatorum" infection in China: a descriptive study. Lancet Infect Dis 2015; 15:196.</a></li><li><a class="nounderline abstract_t">Jia N, Zheng YC, Jiang JF, et al. Human Babesiosis Caused by a Babesia crassa-Like Pathogen: A Case Series. Clin Infect Dis 2018; 67:1110.</a></li></ol></div><div id="topicVersionRevision">Topic 113483 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33501959" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33960362" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Corrigendum to: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22716978" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999229" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27115378" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078770" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atovaquone and azithromycin for the treatment of babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591294" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Azithromycin and the risk of cardiovascular death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283800" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe babesiosis in Long Island: review of 34 cases and their complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801183" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28399851" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9664092" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Persistent parasitemia after acute babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33134419" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Case Report: Overwhelming Babesia Parasitemia Successfully Treated Promptly With RBC Apheresis and Triple Therapy With Clindamycin, Azithromycin, and Atovaquone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405180" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clindamycin and quinine treatment for Babesia microti infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/626449" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32310272" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270894" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31099380" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34664651" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34664646" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clofazimine for Babesiosis: Preclinical Data Support a Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35983604" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiac Complications of Human Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31180581" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19291782" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Red cell exchange transfusion for babesiosis in Rhode Island.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145479" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adjunctive treatment of clinically severe babesiosis with red blood cell exchange: a case series of nineteen patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33179803" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Parasite burden and red blood cell exchange transfusion for babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481763" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538091" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7191475" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of transfusion-transmitted babesiosis by exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552323" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Case records of the Massachusetts General Hospital. Case 6-2014. A 35-day-old boy with fever, vomiting, mottled skin, and severe anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557289" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24104943" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Human babesiosis in Europe: what clinicians need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526674" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Repeat exchange transfusion for treatment of severe babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307834" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Heavy parasitemia in babesiosis treated without adjunctive red cell exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34546166" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recurrence of Human Babesiosis Caused by Reinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853599" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Babesiosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Non-surgical management of spontaneous splenic rupture due to Babesia microti infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622029" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Babesiosis in the immediate postoperative period after splenectomy for trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047477" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27572973" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541469" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181735" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Persistent and relapsing babesiosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036977" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Persistence of babesiosis for&gt;2 years in a patient on rituximab for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34514015" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relapsed Babesia microti Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35242564" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36145484" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Babesia microti Infection in an Immunocompromised Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35684960" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36968958" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790419" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722936" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196774" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Response of babesiosis to a combined regimen of quinine and azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457632" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Human babesiosis in New York State: an epidemiological description of 136 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637139" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941544" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436184" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Emergence of Clinically Relevant Babesiosis in Southwestern Wisconsin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26469785" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Babesiosis Occurrence among the Elderly in the United States, as Recorded in Large Medicare Databases during 2006-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28722598" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26594611" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Human Babesiosis: Pathogens, Prevalence, Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3500663" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Babesiosis, pentamidine, and cotrimoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200568" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Acute babesiosis caused by Babesia divergens in a resident of Kentucky.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607592" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200851" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Babesia divergens-like infection, Washington State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329282" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Possible Transfusion-Transmitted Babesia divergens-like/MO-1 Infection in an Arkansas Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016254" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Probable Locally Acquired Babesia divergens-Like Infection in Woman, Michigan, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7816065" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Infection with a babesia-like organism in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8328736" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Babesiosis in Washington State: a new species of Babesia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129100" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421222" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22168221" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The third described case of transfusion-transmitted Babesia duncani.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350888" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967491" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878956" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The case: hemolysis and acute renal failure. Babesiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751126" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Babesia venatorum Infection in Child, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25539588" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Epidemiological, clinical, and laboratory characteristics of 48 cases of "Babesia venatorum" infection in China: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538646" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Human Babesiosis Caused by a Babesia crassa-Like Pathogen: A Case Series.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
